0Q15 Stock Chart & Stats
$110.97
-$0.89(-0.84%)
At close: 4:00 PM EDT
$110.97
-$0.89(-0.84%)
Day’s Range― - ―
52-Week Range$82.05 - $136.89
Previous CloseN/A
Volume3.01K
Average Volume (3M)7.00K
Market Cap
$175.27B
Enterprise Value$185.82K
Total Cash (Recent Filing)$5.60B
Total Debt (Recent Filing)$32.61B
Price to Earnings (P/E)32.5
Beta0.61
Next Earnings
Oct 21, 2026EPS Estimate
1.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.11
Shares Outstanding1,730,383,300
10 Day Avg. Volume6,940
30 Day Avg. Volume6,996
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.20
Price to Sales (P/S)4.94
P/FCF Ratio29.60
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$124.64Price Target Upside12.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)5.52
Revenue Forecast (FY)$50.31B
Bulls Say, Bears Say
Bulls Say
Diversified Healthcare Portfolio With Recurring DemandAbbott’s presence across four healthcare segments reduces reliance on any single product category or market. Recurring demand for diagnostic reagents, CGM sensors, nutrition, and other consumables can support revenue resilience while differentiated devices and branded generics broaden its long-term growth base.
Strong And Growing Free Cash FlowStrong operating and free cash flow gives Abbott substantial internal funding for research, product launches, acquisitions, debt service, and shareholder returns. Free cash flow also tracks earnings closely, supporting confidence that reported profitability is translating into durable liquidity.
Broad Product Momentum And Innovation PipelineGrowth across diagnostics, cardiovascular devices, nutrition, and diabetes care indicates that Abbott has several active engines rather than relying on one product. New launches, regulatory milestones, and pipeline programs can extend its competitive position and support multi-quarter growth.
Bears Say
Meaningful Increase In DebtThe sharp increase in debt makes Abbott more dependent on sustaining current cash generation and leaves less financial flexibility if operating conditions weaken. Greater leverage can also raise interest and refinancing sensitivity, constraining capital allocation during a downturn.
Recent Margin CompressionLower net margins indicate that recent revenue growth has not fully translated into earnings at the prior rate. If normalization or higher costs persist, margin pressure could limit profit growth, reduce operating leverage, and weaken the cash available for investment and returns.
Ongoing Formula Litigation ExposureThe settlement reduces some uncertainty but does not eliminate Abbott’s exposure to the preterm formula litigation. The remaining lawsuits may generate additional financial costs, management distraction, and reputational pressure around an important nutrition product category.
Abbott Laboratories News
0Q15 FAQ
What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest share price was $82.05 and its highest was $136.89 in the past 12 months.
What is Abbott Laboratories’s market cap?
Abbott Laboratories’s market cap is $175.27B.
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s upcoming earnings report date is Oct 21, 2026 which is in 21 days.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Jul 16, 2026. The company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.277 by $0.033.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories does not currently pay dividends.
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is 1.42.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,730,383,300 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of $1.31 in its last earnings report, beating expectations of $1.277. Following the earnings report the stock price went up 11.469%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Currently, no hedge funds are holding shares in GB:0Q15
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abbott Laboratories Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$124.64 (12.32% Upside)
$124.64 (12.32% Upside)
Blogger Sentiment
Bullish
GB:0Q15 Sentiment 76%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth $46.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.63%
12-Months-Change
Fundamentals
Return on Equity
2.44%
Trailing 12-Months
Asset Growth
30.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
0Q15 Company Deck
0Q15 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall, the call conveyed constructive momentum across Abbott’s diversified portfolio with multiple product and regulatory milestones, gross margin expansion, and raised EPS guidance. Key growth engines — diagnostics (notably cancer testing), nutrition recovery, devices (EP, rhythm management, heart failure) and diabetes/CGM — provide visibility to second-half acceleration. Offsetting risks include a soft respiratory season hurting rapid/molecular diagnostics, China VBP headwinds, structural heart US commercial execution needs, and uncertainty/timing around reimbursement and regulatory approvals for some high-impact products (e.g., CGM reimbursement expansion, Libre Duo FDA clearance). On balance, highlights notably outweigh the lowlights, with achievable near-term drivers and a clear pipeline cadence underpinning positive momentum.View all GB:0Q15 earnings summaries0Q15 Net sales Breakdown
12.49% Established Pharmaceutical Products
19.06% Nutritional Products
20.16% Diagnostic Products
48.25% Medical Devices
0.04% Other
0Q15 Stock 12 Month Forecast
Average Price Target
$124.64
▲(12.32% Upside)
Technical Analysis
Boston Scientific
―
Dexcom
―
Edwards Lifesciences
―
Medtronic
―
GE Healthcare Technologies Inc
―